Hulin, Cyrille http://orcid.org/0000-0002-3749-5161
Beksac, Meral
Goodman, Hugh J.
Spicka, Ivan
Alegre, Adrian http://orcid.org/0000-0002-2423-822X
Prince, Miles
Campana, Frank
Finn, Greg
Le-Guennec, Solenn
Macé, Sandrine
Muccio, Stéphane
Tavernier, Alexandra
Rouchon, Marie-Claude
Richardson, Paul G. http://orcid.org/0000-0002-7426-8865
Funding for this research was provided by:
Sanofi
Article History
Received: 1 April 2021
Revised: 24 June 2021
Accepted: 23 September 2021
First Online: 20 October 2021
Competing interests
: CH has received personal fees from Sanofi and Celgene; MB reports receiving personal fees, advisory board and speakers bureau for Amgen, Celgene, Janssen, Sanofi, and Takeda; HG has nothing to declare; IS reports receiving personal fees, advisory board and speakers bureau for Amgen, Celgene, Janssen, Sanofi, BMS, and Takeda. AA reports having received honoraria derived from his participation on advisory boards, research or consultancy from Amgen, Celgene-BMS, Janssen, Takeda, Sanofi, and Oncopeptides; MP reports personal fees from Celgene; FC was an employee of Sanofi at the time of the study; SLeG, GF, SM, SMu, AT, and MCR are all employees of Sanofi and may hold shares and/or stock options in the company; PR reports grants from BMS, grants and honoraria (advisory committee member from Oncopeptides, Celgene, Takeda, and Karyopharm, honoraria (advisory committee member) from Janssen and Sanofi.